The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2000

Conditions
Sarcoma, KaposiHIV Infections
Interventions
DRUG

Interferon alfa-2b

DRUG

Didanosine

Trial Locations (13)

10021

Memorial Sloan-Kettering Cancer Ctr., New York

14215

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

45267

Univ. of Cincinnati CRS, Cincinnati

46202

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

60611

Northwestern University CRS, Chicago

60612

Rush Univ. Med. Ctr. ACTG CRS, Chicago

63112

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

80262

University of Colorado Hospital CRS, Aurora

94115

Stanford CRS, Palo Alto

02118

Bmc Actg Crs, Boston

Unknown

Washington U CRS, St Louis

00936

Puerto Rico-AIDS CRS, San Juan

Sponsors
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001114 - The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma | Biotech Hunter | Biotech Hunter